Camargo Pharmaceutical Services Announces Education Series on FDA 505(b)(2) Approval Route
CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services, a leading provider of comprehensive drug development services, announced an education series on 505(b)(2) submission to the United States Food and Drug Administration (FDA). The senior management team at Camargo are industry experts in the development of strategic programs utilizing this approval route.